1. Executive Summary
2. Research Methodology
3. Ophthalmology
3.1 Background
3.2 Eye Disorders
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Segment
4.2.2 Market Share by Indication
4.2.3 Market Share by Drug Class
4.2.4 Market Share by Products
4.2.5 Market Share by Product Type
4.2.6 Market Share by Dosage Type
4.2.7 Market Share by Region
5. Market Segmentation
5.1 Segments
5.1.1 Surgical
5.1.1.1 Market Sizing (Actual & Forecasted)
5.1.1.2 Implantable Market Sizing (Actual & Forecasted)
5.1.1.3 Consumables Market Sizing (Actual & Forecasted)
5.1.1.3 Equipment/Others Market Sizing (Actual & Forecasted)
5.1.2 Vision Care
5.1.2.1 Market Sizing (Actual & Forecasted)
5.1.2.2 Contact Lenses Market Sizing (Actual & Forecasted)
5.1.2.3 Contact Lenses Market Sizing (Actual & Forecasted)
5.2 Disease
5.2.1 Retinal Disorder
5.2.1.1 Market Sizing (Actual & Forecasted)
5.2.1.2 Market Share by Disease Type
5.2.1.3 nAMD Market Sizing (Actual & Forecasted)
5.2.1.4 DME/DR Market Sizing (Actual & Forecasted)
5.2.1.5 DME/DR Market Sizing (Actual & Forecasted)
5.2.2 Glaucoma
5.2.2.1 Market Sizing (Actual & Forecasted)
5.2.3 Dry Eye
5.2.3.1 Market Sizing (Actual & Forecasted)
5.3 Drug Class
5.3.1 Anti-Glaucoma Drugs
5.3.2 Dry Eye Drugs
5.3.3 Anti-Infective Drugs
6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Dosage Type
6.1.2.3 Market Share by End-Users
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 Germany
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 The UK
6.2.2.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 China
6.3.2.1 Market Sizing (Actual & Forecasted)
6.3.4 India
6.3.4.1 Market Sizing (Actual & Forecasted)
6.3.4.2 Market Share by Devices
7. Market Dynamics
7.1 Industry Trends & Development
7.1.1 Mergers & Acquisitions
7.1.2 Advent of Novel Drug Delivery Techniques
7.2 Growth Drivers
7.2.1 Prevalence of Eye Disorder
7.2.3 Rising R&D in the Industry
7.2.4 Growing Geriatric Population
7.2.5 Increasing Awareness
7.3 Challenges
7.3.1 High Cost of Diagnosis & Treatment
7.3.2 Patent Expiration of Blockbuster Ophthalmic Drugs
7.3.3 Limited Insurance Coverage
8. Competitive Landscape
8.1 Market Share Analysis
8.2 Financial Analysis
9. Company Profiles
9.1 Novartis AG
9.2 Bausch & Lomb, Inc.
9.3 F.Hoffman La-Roche
9.4 Regeneron Pharmaceuticals, Inc.
9.5 Allergan PLC